Hecto Innovation Co., Ltd. (KOSDAQ:214180)

Achilles Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	335,209	319,472	288,489	262,967	221,041	170,932
Revenue Growth (YoY)	14.53%	10.74%	9.71%	18.97%	29.32%	38.14%
Cost of Revenue	7,817	6,756	8,604	6,561	3,751	2,056
Gross Profit	327,391	312,716	279,885	256,406	217,291	168,876
Selling, General & Admin	244,321	233,634	217,776	195,330	156,877	123,381
Research & Development	5,096	5,015	5,317	10,155	9,712	5,846
Other Operating Expenses	1,772	1,738	1,489	1,378	1,100	789.37
Operating Expenses	277,059	264,272	242,076	220,762	180,126	140,676
Operating Income	50,332	48,444	37,809	35,644	37,165	28,200
Interest Expense	-2,198	-1,967	-1,377	-1,087	-173.23	-251.71
Interest & Investment Income	6,897	6,599	5,105	2,799	1,189	1,287
Earnings From Equity Investments	-3,942	-4,230	-1,645	28.98	47.7	-143.31
Currency Exchange Gain (Loss)	-202.6	-153.68	448.05	-441.92	-260.7	410.24
Other Non Operating Income (Expenses)	2,546	1,995	2,673	2,603	3,404	2,373
EBT Excluding Unusual Items	53,432	50,687	43,013	39,547	41,372	31,875
Gain (Loss) on Sale of Investments	1,334	1,435	-803.98	-1,586	606.11	4,281
Gain (Loss) on Sale of Assets	-101.23	-95.54	-49.27	-28.07	3.13	-167.51
Asset Writedown	-5,546	-5,546	-950.21	-106.32	-	-600.32
Pretax Income	49,119	46,480	41,209	37,826	41,981	35,389
Income Tax Expense	12,704	11,706	9,297	5,649	9,516	6,064
Earnings From Continuing Operations	36,415	34,774	31,912	32,177	32,466	29,325
Minority Interest in Earnings	-7,741	-6,871	-9,114	-2,726	-11,373	-8,995
Net Income	28,674	27,904	22,798	29,452	21,093	20,330
Net Income to Common	28,674	27,904	22,798	29,452	21,093	20,330
Net Income Growth	18.04%	22.39%	-22.59%	39.63%	3.75%	13.47%
Shares Outstanding (Basic)	13	12	12	12	12	12
Shares Outstanding (Diluted)	13	12	12	12	12	12
Shares Change (YoY)	6.24%	4.88%	-3.42%	-0.28%	-1.89%	-6.52%
EPS (Basic)	2292.92	2253.73	1931.15	2409.32	1825.43	1627.09
EPS (Diluted)	2265.93	2229.57	1931.00	2409.00	1721.00	1614.00
EPS Growth	9.96%	15.46%	-19.84%	39.98%	6.63%	20.41%
Free Cash Flow	118,779	101,576	60,470	22,762	81,895	41,434
Free Cash Flow Per Share	9485.20	8204.15	5122.19	1862.05	6680.62	3316.12
Dividend Per Share	490.000	490.000	360.000	420.000	390.000	340.000
Dividend Growth	36.11%	36.11%	-14.29%	7.69%	14.71%	47.83%
Gross Margin	97.67%	97.89%	97.02%	97.50%	98.30%	98.80%
Operating Margin	15.02%	15.16%	13.11%	13.55%	16.81%	16.50%
Profit Margin	8.55%	8.73%	7.90%	11.20%	9.54%	11.89%
Free Cash Flow Margin	35.43%	31.80%	20.96%	8.66%	37.05%	24.24%
EBITDA	67,618	65,247	53,512	49,554	49,221	38,783
EBITDA Margin	20.17%	20.42%	18.55%	18.84%	22.27%	22.69%
D&A For EBITDA	17,285	16,803	15,703	13,910	12,057	10,583
EBIT	50,332	48,444	37,809	35,644	37,165	28,200
EBIT Margin	15.02%	15.16%	13.11%	13.55%	16.81%	16.50%
Effective Tax Rate	25.86%	25.18%	22.56%	14.93%	22.67%	17.13%
Advertising Expenses	-	25,974	28,812	21,703	15,637	9,710

Source: S&P Global Market Intelligence. Standard template. Financial Sources.